| Prev Close | 91.91 |
| Open | 93.25 |
| Day Low/High | 92.13 / 93.34 |
| 52 Wk Low/High | 72.30 / 96.31 |
| Volume | 1.30M |
| Avg Volume | 2.59M |
Novartis AG (NVS)
92.47
0.56
0.61
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.55B |
| Market Cap | 230.89B |
| EPS | 5.50 |
| P/E Ratio | 16.97 |
| Div & Yield | 1.84 (2.05%) |
Latest News
Jim Cramer: The Forbidden City of Stock Sectors
Now, we know that if we got any sort of truce in the trade war, with the exception of the financials, these hated sectors would be loved.
Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space
Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.
Stock of the Day - Tilray
Pot stocks like Tilray have very ambitious valuations but the potential upside (in mergers and, fundamentally in food, drink, supplemental and medical applications) are undeniably immense. The view of a possible rapid rise in revenues and profits (a...
Tilray Stock Lights Up as Partnerships Obscure Profitability Problem
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
Jim Cramer: How to Win Now, With or Without China
If we can advance without China then who the heck knows where we can go with it.
Gilead Shares Fall After Hours as Company Misses on Quarterly Earnings
Medicine is a slow business and I view Gilead Sciences as a hold for now.
Excuse Me, Would You Like Some Cannabis With Your Coffee?
CBD could make coffee an around the clock craze.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Chart of the Day, Part 2: A Closer Look at Constellation's Big Cannabis Bet
Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.
Novartis Stock Is Poised to Rise Another 15% From Here
The stock's performance has been impressive in the past three months.
Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
Tilray Is Now a Top-Tier Cannabis Play
I'd be most interested in buying this name after a cap raise which I expect in the first quarter of 2019.
Tilray Stock Burns Higher With Anheuser-Busch Beverage Deal
Pot stock partnerships are a gateway to gains for cannabis investors.
Tilray Stock Higher Ahead of First Post-Legalization Earnings Release
Tilray will have a lot to tackle this evening.
A Reckless Fed: Market Recon
It's time for the central bank to show the same level of concern for their misplaced aggression.
Tesla Jumps After Judge Makes SEC Settlement Official: LIVE MARKETS BLOG
Tesla will pay $20 million as part of the settlement with Elon Musk paying another $20 million.
Novartis Is Ready to Rally From a Large Base Pattern
Let's check out the latest charts and indicators for some technical guidance.
Jim Cramer: Reefer Madness
Tilray's a disruptive company for many industries.
Gilead's Earnings Fail to Impress
The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.
Biotech Stocks Getting Their Due Respect
Here are two I think will bounce back before the end of the year.
Comcast Is Among 8 Stocks That Are Ready to Change Direction
These names are showing bullish or bearish reversal patterns over the past week.
2 Small Biotechs I Like in the Second Half
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
Closing Bell: LIVE MARKETS BLOG
Markets closed the last day of June trading on a high note Friday.
Novartis Doesn't Appear Ready to Make Healthy Move Higher
The drugmaker may have made a low, but the charts indicate we are a long way from a bottom.
Deutsche Bank Fails Stress Test and 4 Other Stories to Watch Friday Morning
Happy Friday! These are the stories you must know ahead of the opening bell.
Starbucks Leaves a Bitter Taste and Doesn't Suit My Investment Palate Either
For my portfolio, you can't beat this SBUX competitor -- and for a cup of coffee.
